webinar register page

Webinar banner
New Horizons in Cellular Therapy: Harnessing Our Body's Natural Killer Cells to Fight Cancer
Natural killer (NK) cells are specialized immune cells that can recognize and destroy threats, including cancer. Due to their unique capabilities, they have great potential in cancer immunotherapy, with multiple NK cell-based approaches already being evaluated in clinical trials.

In this webinar, we’ll explore how NK cells work and how we might apply them against cancer, with renowned NK cell expert Lewis L. Lanier, Ph.D., and Oscar A. Aguilar, Ph.D., a Cancer Research Institute (CRI) fellow in Dr. Lanier’s lab at the University of California, San Francisco (UCSF).

The “Cancer Immunotherapy and You” webinar series is produced by the Cancer Research Institute and is hosted by our senior science writer, Arthur N. Brodsky, Ph.D. The 2021 series is made possible with generous support from Bristol Myers Squibb and Alkermes.

Oct 27, 2021 01:00 PM in Eastern Time (US and Canada)

Webinar logo
* Required information
Immunotherapy results may vary from patient to patient.


Lewis L. Lanier, Ph.D.
Chair of the Department of Microbiology and Immunology @University of California, San Francisco
A member of the CRI Scientific Advisory Council and National Academy of Sciences, Dr. Lanier has made a number of important discoveries into NK cell biology, especially the receptors that activate and inhibit them. Currently, he serves as the Chair of the Department of Microbiology and Immunology, the American Cancer Society Professor of Microbiology, and the leader of the Cancer Immunology Program at the UCSF Helen Diller Family Comprehensive Cancer Center. Since 1992, he has sponsored seven CRI fellows studying NK cells.
Oscar A. Aguilar, Ph.D.
CRI Postdoctoral Fellow @University of California San Francisco
Dr. Aguilar is a a Cancer Research Institute (CRI) fellow in Dr. Lanier’s lab at the University of California, San Francisco (UCSF). He aims to establish a mouse model that more accurately reflects human CD16-dependent NK cell function. Furthermore, he will test the hypothesis that another aspect of CD16 signaling in NK cells can induce or maintain immunological memory using mouse models of cancer and viral infection. His findings may help expand our knowledge of NK cell biology and provide insights on how to more effectively utilize these cells in the effective treatment of cancer.
Arthur Brodsky, Ph.D.
Senior Science Writer @Cancer Research Institute
Arthur is passionate about translating the exciting advances in cancer immunotherapy, to increase awareness and appreciation of these potentially lifesaving breakthroughs. His belief in the power of immunotherapy―and the importance of communicating the science clearly―inspired him to give a TEDx Talk on the subject. Prior to joining CRI, Arthur earned his Ph.D. in Bioengineering at Clemson University, where he focused on breast cancer metabolism, stem cell expansion, and biopharmaceutical production. He also received his M.S. in Bioengineering from Clemson University and his B.S. in Biomedical Engineering from the University of Miami (FL).